70 related articles for article (PubMed ID: 22413504)
21. Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy.
Dombrovski AY; Lenze EJ; Dew MA; Mulsant BH; Pollock BG; Houck PR; Reynolds CF
J Am Geriatr Soc; 2007 Sep; 55(9):1325-32. PubMed ID: 17767673
[TBL] [Abstract][Full Text] [Related]
22. A double-blind study comparing paroxetine and maprotiline in depressed outpatients.
Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O
Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571
[TBL] [Abstract][Full Text] [Related]
23. Accelerating response in geriatric depression: a pilot study combining sleep deprivation and paroxetine.
Bump GM; Reynolds CF; Smith G; Pollock BG; Dew MA; Mazumdar S; Geary M; Houck PR; Kupfer DJ
Depress Anxiety; 1997; 6(3):113-8. PubMed ID: 9442985
[TBL] [Abstract][Full Text] [Related]
24. [Narcoleptic syndrome as a possible side effect of paroxetine].
Alonso H; Ortí-Pareja M; Jiménez-Jiménez FJ
Rev Neurol; 2004 Dec 1-15; 39(11):1092. PubMed ID: 15597274
[No Abstract] [Full Text] [Related]
25. [Depression and Down syndrome].
Ramstad K; Loge JH; Sponheim E
Tidsskr Nor Laegeforen; 1998 May; 118(14):2153-4. PubMed ID: 9656809
[TBL] [Abstract][Full Text] [Related]
26. The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring.
Zaninelli R; Meister W
Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):9-20. PubMed ID: 9035223
[TBL] [Abstract][Full Text] [Related]
27. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression].
Möslinger-Gehmayr R; Zaninelli R; Contu A; Oberhoff C; Gutschow K; Schindler AE; Staab HJ
Zentralbl Gynakol; 2000; 122(4):195-202. PubMed ID: 10795116
[TBL] [Abstract][Full Text] [Related]
28. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
29. Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.
Serretti A; Gibiino S; Drago A
J Affect Disord; 2011 Jul; 132(1-2):14-25. PubMed ID: 20863574
[TBL] [Abstract][Full Text] [Related]
30. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate].
Vergouwen AC; Bakker A
Ned Tijdschr Geneeskd; 2002 Apr; 146(17):811-2. PubMed ID: 12014241
[TBL] [Abstract][Full Text] [Related]
31. [Patient safety with breast cancer and depression: Concomitant use of paroxetine and tamoxifen].
Muquebil Ali Al Shaban Rodríguez OW; Pérez Castro P; Estrada Alarcón N; Tuñón Gorgojo L
J Healthc Qual Res; 2019; 34(2):110-111. PubMed ID: 30686622
[No Abstract] [Full Text] [Related]
32. [Treatment of non-psychotic depression in outpatient clinic].
Ivanets NN; Kinkul'kina MA
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(5):60-2. PubMed ID: 16768229
[No Abstract] [Full Text] [Related]
33. Increased concentration of corticosteroid-binding globulin due to antidepressant treatment with amitritpyline, but not paroxetine.
Deuschle M; Luppa P; Hamann B; Nonell A; Heuser I
J Psychiatr Res; 2003; 37(1):85-7. PubMed ID: 12482473
[No Abstract] [Full Text] [Related]
34. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis.
Krebs EE; Gaynes BN; Gartlehner G; Hansen RA; Thieda P; Morgan LC; DeVeaugh-Geiss A; Lohr KN
Psychosomatics; 2008; 49(3):191-8. PubMed ID: 18448772
[TBL] [Abstract][Full Text] [Related]
35. Dopaminergic sensitivity and prediction of antidepressant response.
Watson S; Young A
J Psychopharmacol; 2000; 14(4):419. PubMed ID: 11198062
[No Abstract] [Full Text] [Related]
36. Drugs or psychotherapy for the elderly?
Harv Ment Health Lett; 2001 Oct; 18(4):7. PubMed ID: 11684507
[No Abstract] [Full Text] [Related]
37. Psychopathological dimensions of tinnitus and psychopharmacologic approaches in its treatment.
Belli H; Belli S; Oktay MF; Ural C
Gen Hosp Psychiatry; 2012; 34(3):282-9. PubMed ID: 22285367
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of adepress (paroxetine) in the treatment of depression in patients with chronic cerebral ischemia in the late recovery phase of ischemic stroke with the estimation of the velocity of passive transmembrane ion transport].
Khasanova DR; Zhitkova IuV; Safiullina AA; Oslopov VN; Khasanov NR
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(3 Pt 2):27-30. PubMed ID: 22677766
[TBL] [Abstract][Full Text] [Related]
39. SSRI use by tinnitus patients: interactions between depression and tinnitus severity.
Folmer RL; Shi YB
Ear Nose Throat J; 2004 Feb; 83(2):107-8, 110, 112 passim. PubMed ID: 15008444
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of olfactory reference syndrome with paroxetine.
Teraishi T; Takahashi T; Suda T; Hirano J; Ogawa T; Kuwahara T; Nomura S
J Neuropsychiatry Clin Neurosci; 2012; 24(1):E24. PubMed ID: 22450633
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
